Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could End-of-Life care for blood cancer patients be done at home?

NCT ID NCT04690205

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a hospital-at-home care model can help people with advanced blood cancers receive end-of-life care at home instead of in the hospital. Participants use remote monitoring and home-based supportive care, with researchers tracking how many enroll and complete daily symptom assessments. The goal is to see if this approach is practical and acceptable for patients, caregivers, and doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a hospital-at-home care model with remote monitoring and home-based supportive care
What this could lead to
If successful, this approach could offer a more comfortable, home-based option for end-of-life care in blood cancer patients, potentially improving quality of life.
What could go wrong
This is a small pilot study focused on feasibility, not effectiveness. It may not show clear benefits, and home care may not suit all patients or caregivers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Feb 2021

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18 or older * diagnosed with relapsed or refractory hematologic malignancy * must be receiving treatment with non-curative intent or supportive care alone based on the intent of chemotherapy as reported in order entry or Electronic Health Record * deemed eligible to receive EOL care at home based on the primary oncologist's assessment * Able to communicate and respond to questionnaires in English or with the assistance of an interpreter. * residing within 50 miles of MGH. Of note, patients requiring supportive transfusions in the oncology clinic will still be eligible to participate. Exclusion Criteria: * Those with uncontrolled psychiatric illness or impaired cognition interfering with their ability to understand study procedures and provide written informed consent as determined by the primary oncologist.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancy

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.